Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction
PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) — Carmell Corporation (Nasdaq:CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.